Impressum

Vgl. http://www.destatis.de/DE/ZahlenFakten/Indikatoren/LangeReihen/Bevoelkerung/lrbev04.html?cms_gtp=151956_list%253D1&https=1 (15.1.2015)

R. Luengo-Fernandez, J. Leal, A. Gray, R. Sullivan: Economic burden of cancer across the European Union: a population-based cost analysis. The Lancet Oncology 2013 (14), S. 1165–74.

T. Fojo, S. Mailankody, A. Lo: Unintended consequences of expensive cancer therapeutics – the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngology – Head & Neck Surgery 2014, Dec (140/12), S. 1225–36.

Vgl. http://www.dkfz.de/de/krebsatlas/gesamt/anhang.html (16.1.2015)

http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf (16.1.2015)

D. Hanahan, R.A.Weinberg: The Hallmarks of Cancer. Cell 2000 (100), S. 57–70.

J. Tabin, S.M. Bradley, C.I. Bargmann, R.A. Weinberg et al.: Mechanism of activation of a human oncogene. Nature 1982 (300), S. 143–49.

Vgl. H.G. Beger, B. Rau et al.: Bauchspeicheldrüsenkrebs – Heilungschancen minimal. Deutsches Ärzteblatt 2008 (105/14), S. 255–62.

M. Deininger, E. Buchdunger, B.J. Druker: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 (105), S. 2640–53.

Vgl. Die ZEIT vom 5. April 2013.

D. Hanahan., R.A. Weinberg: The Hallmarks of Cancer. Cell 2000 (100/1), S. 57–70, und dies.: The Hallmarks of cancer: the next generation. Cell 2011 (144/5), S. 646–74.

http://www.binfo.ncku.edu.tw/TAG/GeneDoc.php (11.3.2015)

Ebd.

E. Bianconi et al.: An estimation of the number of cells in the human body. Annals of Human Biology 2013 (40/6), S. 463–71.

Robert Koch Institut: Gesundheitsberichterstattung des Bundes Heft 36. Prostataerkrankungen. Berlin 2007, S. 8.

J. Monge, M. Kricum et al.: Fibrous Dysplasia in a 120,000+ Year Old Neandertal from Krapina, Croatia. PlosOne 2013.

http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-modern-knowledge-and-cancer-causes (23.1.2015)

A.L. Murphree, W.F. Benedict: Retinoblastoma: clues to human oncogenesis. Science 1984 (223/4640), S. 1028–33.

M. Zhao, J. Sun, Z. Zhao: TSGene: a web resource for tumor suppressor genes. Nucleic Acids Research 2013 (41), D970-D976 (23.1.2015).

M. Jokela, G.D. Batty et al.: Is personality associated with cancer incidence and mortality? An individual participant metaanalysis of 2156 incident cancer cases among 42843 men and women. British Journal of Cancer 2014 (110/7), S. 1820–24.

K. Hemminki, X. Li., K. Czene: Familial risk of cancer: data for clinical counseling and cancer genetics. International Journal of Cancer 2004 (108/1), S. 109–14.

T. Pal, S.T. Vadaparampil: Genetic Risk Assessments in Individuals at High Risk for Inherited Breast Cancer in the Breast Oncology Care Setting. Cancer Control 2012 (19/4), S. 255–66.

http://www.darmkrebs.de/ueberblick/risiko-fuer-darmkrebs/familiaeres-risiko/ (23.1.2015)

E.S. Epel et al.: Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences of the United States of America (101/49), S. 17312–5.

D. Ribbatti: Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis 2008 (11/1), S. 3–10.

C.G. Willett, Y. Boucher: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 2004 (10/2), S. 145–47.

A.D. Wagner, C. Thomssen, J. Haerting, S. Unverzagt: Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews 2012 (7).

E.J. Lipson, C.G. Drake: Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clinical Cancer Research 2011 (17), S. 6958–62.

C. Zielinski, S. Knapp, C. Mascaux, F. Hirsch: Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Annals of Oncology 2013 (24/5), S. 1170–79.

http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf (22.4.2015)

D. Bonnet, J.E. Dick: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 1997 (3/7), S. 730–37.

D. Hanahan: Rethinking the war on cancer. Lancet 2014 (383), S. 558–63.

S. Mukherjee: Der König aller Krankheiten: Krebs – eine Biografie. Köln 2015, S. 392f.

Ebd., S. 393ff.

E.A. Richter: Der Fall Bezwoda. Deutsches Ärzteblatt 2000 (97/12), A-752/B-614/C-574.

V. Zylka-Menhorn: Forschungsbetrug – Fall Herrmann/Brach: Gutachter bestätigen den dringenden Verdacht der Manipulation. Deutsches Ärzteblatt 1997 (94/42), A-2716/B-2311/C-2175.

P.B. Bach: Limits on Medicare’s ability to control rising spending on cancer drugs. New England Journal of Medicine 2009 (360/66), S. 626–33.

Vgl.: T. Reya: Stem cells, cancer, and cancer stem cells. Nature 2001(414/6859), S. 105–11.

Vgl. Robert Koch Institut: Krebs in Deutschland 2009/2010. Berlin 2013.

Vgl.: P. Traxler: Tyrosine kinases as targets in cancer therapy – successes and failures. Expert Opinion on Therapeutic Targets 2003 (7/2), S. 215–34.

P.C. Nowell, D.A. Hungerford: Chromosome studies on normal and leukemic human leukocytes. Journal of the National Cancer Institute 1960 (25), S. 85–109.

H. Kantarijan et al.: Drug evaluation: Nilotinib – a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 2007 (10/7), S. 468–79.

Ebd.

K. Claiborn: Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award. Journal of Clinical Investigation 2011 (121/4), S. 1227–28.

Vgl. Mukherjee 2015, S. 536f.

Vgl. S.G. O’Brien, B.J. Druker et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloidleukemia. New England Journal of Medicine 2003 (348/11), S. 994–1004.

http://de.statista.com/statistik/daten/studie/302733/umfrage/umsatz-von-novartis-mit-dem-medikament-gleevec-glivec/ (13.2.2015)

U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2014. Berlin/Heidelberg 2014, S. 842.

Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancerdrugs: from the perspective of a large group of CML experts. Blood 2013 (121/22), S. 4439–42.

B. Vogelstein et al.: Cancer genome landscapes. Science 2013 (339/6127), S. 1546–58.

http://www.nobelprize.org/events/nobel-week-dialogue/2012/panellists/bert-vogelstein.html (4.5.2015)

B. Vogelstein et al.: Cancer genome landscapes. Science 2013 (339/6127), S. 1546–58.

Ebd.

U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2013. Berlin/Heidelberg 2013, S. 57ff.

Ebd., S. 65ff.: Gemeinsamer Bundesausschuss: Tragende Gründe 1 zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Crizotinib. Berlin 2013.

T. Fojo, S. Mailankody, A. Lo: Unintended consequences of expensive cancer therapeutics – the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngology – Head & Neck Surgery 2014, Dec (140/12), S. 1225–36.

A. Reese, P. Pech.: Tyrosinkinasehemmer zur oralen Tumortherapie. Fortbildungstelegramm Pharmazie 2013 (7/4).

U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2014. Berlin/Heidelberg 2014, S. 833.

U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2014. Berlin/Heidelberg 2014, S. 842.

B. Vogelstein et al.: Cancer genome landscapes. Science 2013 (339/6127), S. 1546–58.

C.G. Begley, L.M. Ellis: Drug development: Raise standards for preclinical cancer research. Nature 2012 (483/7391), S. 531–33.

http://www.cancer.gov/clinicaltrials/noteworthy-trials/match (3.3.2015)

http://www.nytimes.com/2015/02/26/health/fast-track-attacks-on-cancer-accelerate-hopes.html?hpw&rref=health&action=click&pgtype=Homepage&module=well-region&region=bottom-well&WT.nav=bottom-well&_r=1 (3.3.2015)

C. Shuptrine, R. Surana, L.M. Weiner: Monoclonal Antibodies for the Treatment of Cancer. Seminars in Cancer Biology 2012 (22/1), S. 3–13.

H.M. Shepard., P. Jin, D.J. Slamon, Z. Pirot, D.C. Maneval: Trastuzumab (Herceptin). Handbook of Experimental Pharmacology 2008 (181), S. 183–219.

http://www.nytimes.com/2005/07/12/business/12cancer.html?pagewanted=all (18.3.2015)

http://www.cancer.ucla.edu/Index.aspx?page=644&recordid=678 (4.5.2015)

B. Huang, M. Warner, J.A. Gustafsson: Estrogen receptors in breast carcinogenesis and endocrine therapy. Molecular and Cellular Endocrinology 11/2014, pii: S0303–7207(14)00371–2.

C. Brisken: Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nature Reviews Cancer 2013 (13/6), S. 385–96.

Vgl. Robert Koch Institut: Krebs in Deutschland 2009/2010. Berlin 2013. S. 68.

B.D. Lehmann, J.A. Pietenpol: Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. The Journal of Pathology 2014 (232/2), S. 142–50.

B.R. Zetter: The scientific contributions of M. Judah Folkman to cancer research. Nature Reviews Cancer 2008 (8/8), S. 647–54; http://www.nytimes.com/2008/01/16/us/16folkman.html?_r=1& (27.2.2015)

I. Kümler, O.G. Christiansen, D.L. Nielsen: A systematic review of bevacizumab efficacy in breast cancer. Cancer Treatment Reviews 2014 (40/8), S. 960–73.

http://de.statista.com/statistik/daten/studie/312974/umfrage/pharmaindustrie-top-unternehmen-nach-gewinnspanne/ (18.2.2015)

W.D. Ludwig: Anforderungen an die Arzneimittelentwicklung in der Onkologie. Im Druck; L.M. Ellis et al.: American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Journal of Clinical Oncology 2014 (32/12), S. 1277–80.

Ebd.

C. Brettschneider, D. Lühmann, H. Raspe: Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technology Assessment 2011 (7/Dok. 01).

A. Aggarwal et al.: Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. Journal of Cancer Policy 2014 (2), S. 1–11.

http://www.england.nhs.uk/ourwork/pe/cdf/ (23.4.2015)

Ebd.; eigene Berechnungen.

http://www.washingtonpost.com/blogs/wonkblog/wp/2014/11/05/voters-in-arizona-just-overwhelmingly-backed-a-dallas-buyers-club-law-will-it-help-patients/ (18.2.2015)

http://www.zeit.de/2005/21/Pharmafirmen_neu (20.4.2015)

W.D. Ludwig, G. Schott: Neue Arzneimittel in der Onkologie: Merkmale klinischer Zulassungsstudien und Argumente für die rasche Durchführung unabhängiger klinischer Studien nach der Zulassung. Onkologie 2013 (36/2), S. 17–22.

http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2015/03/WC500184522.pdf (5.5.2015)

E. Zerhouni: EMA – The Next 5 Years. The Innovators Perspective. Vortrag zum 20. Jubiläum der EMA.

Vgl. U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2014. Berlin/Heidelberg 2014; U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2006. Berlin/Heidelberg 2006.

U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2014. Berlin/Heidelberg 2014.

http://archive.bcaction.org/index.php?page=newsletter-89h (18.2.2015)

W.D. Ludwig: Beispiele für Arzneimittel(des)information an speziellen Präparategruppen – «Off-Label-Use» in der Onkologie. Vortrag bei der Jubiläumsveranstaltung aus Anlass des 40. Jahrgangs. Der Arzneimittelbrief vom 2. September 2006, Berlin.

E. Dolgin: Big pharma moves from ‹blockbusters› to ‹niche busters›. Nature Medicine 2010 (16/8), S. 837.

W.D. Ludwig: Anforderungen an die Arzneimittelentwicklung in der Onkologie. Im Druck.

M. Hallek: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology 2015, May (90/5), S. 446–60

S.C. Sodergren et al.: Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumors on behalf of the EORTC Quality of Life Group. Critical Reviews in Oncology/Hematology 2014 (91/1), S. 35–46.

Vgl. D. Iacono: Future options for ALK-positive non-small cell lung cancer. Lung Cancer 2015 (87/3), S. 211–19.

Vgl. http://www.nytimes.com/2015/03/03/science/arming-the-immune-system-against-cancer.html?_r=0 (4.3.2015)

M.F. Krummel, J.P. Allison: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. Journal of Experimental Medicine 1995 (182/2), S. 459–65.

D.R. Leach, M.F. Krummel, J.P. Allison: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996 (271/5256), S. 1734–36.

Vgl. E.J. Lipson, C.G. Drake: Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clinical Cancer Research 2011 (17), S. 6958–62; F.S. Hodi et al.: Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010 (363/8), S. 711–23.

R.E. Sherman et al.: Expediting drug development – the FDA’s new «breakthrough therapy» designation. New England Journal of Medicine 2013 (369/20), S. 1877–80.

M. Maio et al.: Five-Year Survival Rates for Treatment-Naive Patients With Advance Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase II I Trial. Journal of Clinical Oncology 2015 (33/10), S. 1191–96.

Vgl. http://www.sfgate.com/health/article/Jim-Allison-confronts-cancer-critics-with-5405290.php (19.3.2015)

D.S. Shin, A. Ribas: The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Current Opinion in Immunology 2015 (33C), S. 23–35.

http://www.aerzteblatt.de/nachrichten/46123/Melanom-Lebensverlaengerung-mit-zwei-neuen-Medikamenten (19.3.2015)

Vgl. Ein Texaner bändigt den Krebs, in: Der Tagesspiegel vom 18.3.2015.

http://www.nytimes.com/2015/03/31/science/the-condition-cancer-research-is-in.html (20.4.2015)

Vgl. http://www.aerzteblatt.de/nachrichten/61143/PD1-Inhibitoren-Erste-Erfolge-beim-Hodgkin-Lymphom?s=keytruda (19.3.2015)

Vgl. J.L. Godwin et al.: Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discovery Medicine 2014 (18/101), S. 341–50.

E.B. Garon et al.: Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine 2015.

D.S. Shin, A. Ribas: The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Current Opinion in Immunology 2015 (33C), S. 23–35.

S.M. Corsello et al.: Endocrine side effects induced by immune checkpoint inhibitors. The Journal of Clinical Endocrinology and Metabolism 2013 (98/4), S. 1361–75.

E. Sharon et al.: Immune checkpoint inhibitors in clinical trials. Chinese Journal of Cancer 2014 (33/9), S. 434–44.

J.N. Graff , E.D. Chamberlain: Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evidence 2014 (10), S. 1–10.

http://dealbook.nytimes.com/2014/11/10/dendreon-maker-of-prostate-cancer-drug-provenge-files-for-bankruptcy/?_r=0 (19.3.2015)

Vgl. J.L. Godwin et al.: Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discoverv Medicine 2014 (18/101), S. 341–50.

J.N. Kochenderfer, S.A. Rosenberg: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature Reviews Clinical Oncology 2013 (10/5), S. 267–76.

Vgl. http://www.answersincme.com/content/evolving-role-immunotherapy-and-rational-combination-strategies-melanoma (20.3.2015)

S. Bhatia et al.: Systemic therapy of metastatic melanoma: on the road to cure. Oncology (Williston Park) 2015 (29/2), S. 126–35.

N. Hawkes: Many cancer deaths could be eliminated by greater awareness and access to latest treatments, report says. British Medical Journal 2015;350:h223.

B. Vogelstein et al.: Cancer genome landscapes. Science 2013 (339/6127), S. 1546–58)

S. Mailankody, V. Prasad: Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. JAMA Oncology, online veröffentlicht am 2. April 2015.

H. Kantarijan, S.V. Rajkumar: Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? Mayo Clinic Proceedings 2015 (90/4), S. 500–04.

http://www.nytimes.com/2014/11/19/upshot/calculating-the-real-costs-of-developing-a-new-drug.html?abt=0002&abg=1 (22.4.2015)

D.W. Light, R. Warburton: Demythologizing the high costs of pharmaceutical research. BioSocieties 2011 (6), S. 34–50.

H. Kantarijan, S.V. Rajkumar: Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? Mayo Clinic Proceedings 2015 (90/4), S. 500–04.

http://www.nytimes.com/2015/03/31/science/the-condition-cancer-research-is-in.html (22.4.2015)

V. Shankaran, S. Ramsey: Addressing the Financial Burden of Cancer Treatment. JAMA Oncology, online veröffentlicht am 9. April 2015.

http://www.nytimes.com/2015/04/28/us/obama-proposes-that-medicare-be-given-the-right-to-negotiate-the-cost-of-drugs.html?_r=0 (6.5.2015)

H.V. Hogerzeil: Big Pharma and social responsibility – the Access to Medicine Index. New England Journal of Medicine 2013 (369/10), S. 896–99.

Vgl. Statistisches Bundesamt: Bevölkerung Deutschlands bis 2060.12. koordinierte Bevölkerungsvorausberechnung. Wiesbaden 2009.

Vgl. Robert Koch Institut: Krebs in Deutschland 2009/2010. Berlin 2013, S. 22.

R. Luengo-Fernandez et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncology 2013 (14), S. 1165–74.

C. Allemani et al.: Global surveillance of cancer survival 1995–2009: analysis of individual data for 25676887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015 (385/9972), S. 977–1010.

R. Luengo-Fernandez et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncology 2013 (14), S. 1165–74.

S. Soneji, J. Yang: New analysis reexamines the value of cancer care in the United States compared to Western Europe. Health Affairs 2015 (34/3), S. 390–97.

Vgl. T. Spinks et al.: Ensuring Quality Cancer Care: A Follow-Up Review of the Institute of Medicine’s Ten Recommendations for Improving the Quality of Cancer Care in America. Cancer 2012 (118/10), S. 2571–82; und C. Wild, N. Patera: Measuring quality in cancer care: overview of initiatives in selected countries. European Journal of Cancer Care 2013 (22/6), S. 773–81.

http://www.cancer.org/treatment/childrenandcancer/whenyourchildhascancer/childrendiagnosedwithcancerunderstandingthehealthcaresystem/children-diagnosed-with-cancer--understanding-the-health-care-system-comprehensive-care (4.3.2015)

A.M. Nick et al.: A framework for a personalized surgical approach to ovarian cancer. Nature Reviews Clinical Oncology 2015.

A. Mariotto et al.: Projections of the cost of cancer care in the United States: 2010–2020. Journal of the National Cancer Institute 2011 (103/2), S. 117–28.

U. Schwabe, D. Paffrath (Hg.): Arzneiverordnungsreport 2014. Berlin/Heidelberg 2014, S. 821.

Sachverständigenrat zur Begutachtung der Gesamtwirtschaftlichen Entwicklung (Ed.): Herausforderungen des demografischen Wandels. Expertise im Auftrag der Bundesregierung, Expertisen, Sachverständigenrat zur Begutachtung der Gesamtwirtschaftlichen Entwicklung. Wiesbaden 2011, S. 15ff.

A.B. Mariotto et al.: Projections of the Cost of Cancer Care in the United States: 2010–2020. Journal of the National Cancer Institute 2011 (103/2).

Vgl. American Cancer Society. Cancer Facts & Figures 2014. Atlanta 2014.

IMS Institute for Healthcare Informatics: Global Outlook for Medicines through 2018. Parsippany 2014.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Crizotinib – Nutzenbewertung gemäß § 35a SGB V. Köln 2013.

http://www.dgho.de/informationen/nachrichten/Crizotinib%20DGHO%20Stellungnahme.pdf (24.3.2015)

Siehe dazu T. Tecic, M. Walgenbach, E.A.M. Neugebauer: Messung und Bewertung von Lebensqualität. In: K. Lauterbach, M. Lüngen, M. Schrappe: Gesundheitsökonomie, Management und Evidence-based Medicine. Handbuch für Praxis, Politik und Studium.³ Stuttgart 2010.

S. Djalalov, J. Beca, J.S. Hoch et al.: Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. Journal of Clinical Oncology 2014 (32/10), S. 1012–19.

L.M. Fleck: Just Caring: Can We Afford the Ethical and Economic Costs of Circumvening Cancer Drug Resistance? Journal of Personalized Medicine 2013(3), S. 124–43.

E.A. Perez et al.: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology 2011, Sep 1 (29/25), S. 3366–73.

E.B. Garon: Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine 2015, May 21 (372/21), S. 2018–28.

Vgl. http://www.nytimes.com/2015/01/15/opinion/why-drugs-cost-so-much.html?_r=0 (24.3.2015)

Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancerdrugs: from the perspective of a large group of CML experts. Blood 2013 (121/22), S. 4439–42.

B. Vogelstein B.: Cancer genome landscapes. Science 2013 (339/6127), S. 1546–58.

http://www.england.nhs.uk/ourwork/pe/cdf/ (24.3.2015)

Vgl. Deutscher Ethikrat: Nutzen und Kosten im Gesundheitswesen – Zur normativen Funktion ihrer Bewertung. Stellungnahme. Berlin 2011.

T.J. Smith, B.E. Hillner: Bending the cost curve in cancer care. New England Journal of Medicine 2011 (364/21), S. 2060–65.

S. Dhillon: Palbociclib: First Global Approval. Drugs 2015 (75/5), S. 543–41.

R.S. Finn: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncology 2015 (16/1), S. 25–35.

http://www.nytimes.com/aponline/2015/02/03/us/politics/ap-us-breast-cancer-drug-fda.html (25.3.2015)

http://www.spiegel.de/gesundheit/diagnose/arzneimittel-5-fluoruracil-wichtigstes-krebsmedikament-5-fu-geht-aus-a-868025.html (19.6.2015)

T.J. Smith, B.E. Hillner: Bending the cost curve in cancer care. New England Journal of Medicine 2011 (364/21), S. 2060–65; D. Sulmasy, B. Moy: Debating the oncologist’s role in defining the value of cancer care: our duty is to our patients. Journal of Clinical Oncology 2014 (32/36), S. 4039–41.

L.H. Aiken et al.: Nurse staffing and education and hospital mortality in nine European countries: a retrospective observational study. Lancet 2014 (383/9931), S. 1824–30.

W. Kymlicka: Contemporary Political Philosophy. An Introduction. Oxford 201².

N. Daniels: Just Health Care. Cambridge 1985.

Vgl. J. Rawls: Eine Theorie der Gerechtigkeit. Frankfurt/M. 1979.

Vgl. P.C. Gøtzsche: Tödliche Medizin und organisierte Kriminalität: Wie die Pharmaindustrie unser Gesundheitswesen korrumpiert. München 2014.

Vgl. G. Maio: Geschäftsmodell Gesundheit. Frankfurt 2014.

http://www.br.de/radio/bayern2/wissen/iq-wissenschaft-und-forschung/medikamente-studien100.html (25.3.2015)

Vgl. http://www.akdae.de/ (25.3.2015)

S. Majorczyk et al.: Das Handbuch gegen Krebs. München 2014.

A. Bruns, J. Mohr: Spiegel Wissen: Diagnose Krebs. Hamburg 2014.

D. Hanahan: Rethinking the war on cancer. Lancet 2014 (383/9916), S. 558–63.

V. Sharma et al.: Challenges of cancer control in developing countries: current status and future perspective. Future Oncology 2011 (7/10), S. 1213–22.

S. Huang: The war on cancer: lessons from the war on terror. Frontiers in Oncology 2014 (4), S. 293.

G. Glaeske et al.: Sicherstellung einer effizienten Arzneimittelversorgung in der Onkologie. Gutachten im Auftrag des Bundesministeriums für Gesundheit. Bremen 2010.

http://www.genomicsengland.co.uk/ (26.3.2015)

http://dietmar-hopp-stiftung.de/medizin/ (18.6.2015)

Vgl. http://www.vdek.com/presse/daten/b_versicherte.html (26.3.2015)

K. Gogineni et al.: Patient Demands and Requests for Cancer Tests and Treatments. JAMA Oncology 2015 (1/1), S. 33–9.

K. Chamie et al.: Population-Based Assessment of Determining Treatments for Prostate Cancer. JAMA Oncology 2015 (1/1), S. 60–7.

J. Hersch et al.: Use of a decision aid including information on overdetection to support informed choice about breast cancerscreening: a randomised controlled trial. Lancet 2015, Apr 25 (385/9978), S. 1642–52.

W.D. Ludwig: Die Behandlung von Krebspatienten am Lebensende – wann kann weniger mehr sein? Frankfurter Forum, 11. April 2015.

Ebd.

D.Y. Heng et al.: Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology 2014 (1), S. 149–54.

J.S. Temel et al.: Early palliative care for patients with metastatic non-small-cell lung cancer. The New England Journal of Medicine 2010 (363/8), S. 733–42.

S.R. Connor et al.: Comparing hospice and nonhospice patient survival among patients who die within a three-year window. Journal of Pain and Symptom Management 2007 (3), S. 238–46.

Vgl. Deutscher Bundestag: Drucksache 18/2529 vom 12.9.2014.

Vgl. G. Neubauer, A. Neubauer: Krebs im Fokus – Häufigkeit und Kosten in Deutschland. Limburg 2012.

W.D. Ludwig, J. Schildmann: Kostenexplosion in der medikamentösen Therapie onkologischer Erkrankungen. Ursachen, Lösungsansätze und medizinethische Herausforderungen. Der Onkologe 2015. Im Druck.

W.D. Ludwig: Anforderungen an die Arzneimittelentwicklung in der Onkologie. Im Druck.

Vgl. Deutscher Bundestag: Drucksache 18/188 vom 17.12.2013